Accessibility Menu
Celyad Oncology logo

Celyad Oncology(OTC) CLYYF

Current Price$0.20
Market Cap$8.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-98%
1 Year-60%
1 Month-20%
Celyad Oncology last closing stock price
MetricPriceDate
Last closeUSD 0.202026-07-10
Celyad Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-20%USD 0.252026-04-23
1 month-20%USD 0.252026-04-23
3 month-42.86%USD 0.352026-03-06
Year to date+33.33%USD 0.152025-12-26
1 year-60%USD 0.502025-05-30
3 year-63.12%USD 0.542023-07-10
5 year-97.81%USD 9.152021-04-20
Since inception-99.65%USD 56.882014-01-15

Celyad Oncology Financials at a Glance

Market Cap

$8.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€207.00K

Net Income (TTM)

-€5.00M

EPS (TTM)

$0.03

P/E Ratio

6.69

Dividend

$0.00

Beta (Volatility)

-0.93 (Low)

Price

$0.20

Volume

100

Open

$0.20

Previous Close

$0.20

Daily Range

$0.20 - $0.20

52-Week Range

$0.15 - $0.53

Estimated Earnings Date

Sep 23, 2026

CLYYF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Celyad Oncology

Celyad Oncology S.A. is a clinical-stage biopharmaceutical company focused on developing innovative chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. The company is advancing several promising candidates through various stages of clinical trials, aiming to address significant unmet medical needs in oncology.

Products and Services
  • CYAD-101: Allogeneic CAR-T candidate in Phase 1b for metastatic colorectal cancer
  • CYAD-211: Allogeneic CAR-T therapy in Phase 1 for relapsed/refractory multiple myeloma
  • CYAD-02: Autologous CAR-T candidate in Phase 1 for acute myeloid leukemia
Growth Outlook
  • Strong pipeline with multiple CAR-T therapies in clinical trials
  • Collaborations with Novartis and Horizon Discovery enhance research capabilities
  • Potential market expansion as CAR-T therapies gain acceptance in oncology
Financial Highlights
  • Recent quarterly revenue of 6,997 EUR, showing growth potential
  • TTM revenue of 69,997 EUR, indicating a developing revenue stream
  • Cash and cash equivalents of 1,707,360 EUR as of Q4 2025, supporting ongoing operations
Celyad Oncology S.A. is positioned in the biotechnology sector, focusing on innovative cancer therapies. The company’s clinical programs, particularly in CAR-T cell therapies, are designed to address critical needs in cancer treatment. With a robust pipeline and strategic partnerships, Celyad is well-placed to capitalize on the growing demand for advanced cancer therapies. Recent financial data indicates a developing revenue stream, with a notable cash position that supports ongoing research and development efforts. The company's focus on allogeneic CAR-T therapies may provide a competitive edge in the rapidly evolving oncology landscape.
AI Generated • Jul 17, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

CEO

Matthew R. Kane, MBA

Website

www.celyad.com

Headquarters

Mont-Saint-Guibert, WA 1435, BE

CLYYF Financials

Key Financial Metrics (TTM)

Gross Margin

9195.24%

Operating Margin

-34200.00%

Net Income Margin

3833.33%

Return on Equity

-242.11%

Return on Capital

-294.83%

Return on Assets

18.73%

Earnings Yield

14.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

44.76M

Volume

100

Avg. Volume

131.661

Financials (TTM)

Gross Profit

€2.10M

Operating Income

-€13.04M

EBITDA

-€12.21M

Operating Cash Flow

-€13.16M

Capital Expenditure

-€118.00K

Free Cash Flow

-€13.16M

Cash & ST Invst.

€1.71M

Total Debt

€0.00

Celyad Oncology Performance Analysis

Celyad Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 0N/A
20232023-12-31EUR 110,274N/A
20242024-12-31EUR 201,19482.4%
20252025-12-31EUR 23,700-88.2%
Celyad Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-75.9%
Q42024-12-311128.6%
Q22025-06-30-91.9%
Q42025-12-31-50.0%
Celyad Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -1.90-5.2%
20232023-12-31EUR -0.36-81.4%
20242024-12-31EUR -0.15-57.2%
20252025-12-31EUR 0.02N/A
Celyad Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3025.0%
Q42024-12-3144.1%
Q22025-06-30-32.2%
Q42025-12-31224.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

€7.00K

-87.9%

Gross Profit

€2.13M

+6349.3%

Gross Margin

304.17%

N/A

Market Cap

$8.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$526.61K

N/A

Employees

17

N/A

Net Income

€4.50M

+195.7%

EBITDA

-€3.43M

+23.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

€1.71M

-65.7%

Total Debt

€0.00

-100.0%

Accounts Receivable

€791.70K

+23.3%

Inventory

€0.00

N/A

Long Term Debt

€0.00

-100.0%

Short Term Debt

€0.00

-100.0%

Return on Assets

18.73%

N/A

Return on Invested Capital

-2.90%

N/A

Free Cash Flow

-€3.62M

+51.4%

Operating Cash Flow

-€3.62M

+47.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QNRXQuoin Pharmaceuticals, Ltd.
$4.38+2.70%
PSTVPlus Therapeutics, Inc.
$3.82-2.55%
SONNSonnet BioTherapeutics Holdings, Inc.
$1.26-59.35%
KPRXKiora Pharmaceuticals, Inc.
$2.53+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.00+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%
NOKNokia
$10.28-0.03%

Questions About CLYYF

What is the current price of Celyad Oncology?

Celyad Oncology is trading at $0.20 per share.

What is the 52-week range for Celyad Oncology?

Over the past 52 weeks, Celyad Oncology has traded between $0.15 and $0.53.

How much debt does Celyad Oncology have?

As of the most recent reporting period, Celyad Oncology reported total debt of €0.00.

How much cash does Celyad Oncology have on hand?

Celyad Oncology reported €2.01M in cash and cash equivalents in its most recent financial results.

What is Celyad Oncology’s dividend yield?

Celyad Oncology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services